Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.50 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.50 |
| ▸ | ACVRL1 | P37023 | 16/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15047989 | 0.82 | FGFR1 (0.41) | FGFR1FGFR3 | |
| SCHEMBL15023976 | 0.82 | FGFR1 (0.41) | FGFR1FGFR3 | |
| SCHEMBL15020407 | 0.80 | FGFR1 (0.47) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL15018905 | 0.80 | ACVRL1 (0.42) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL15047962 | 0.69 | ACVRL1 (0.33) | ACVRL1 | |
| SCHEMBL15023043 | 0.68 | ACVRL1 (0.30) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL279164 | 0.68 | FGFR1 (0.49) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL15047911 | 0.68 | FGFR1 (0.35) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL22315380 | 0.68 | FGFR1 (0.39) | FGFR1FGFR3ACVRL1 | |
| SCHEMBL15047972 | 0.68 | TNK2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153745-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| US-20220153745-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2022-05-19 | — | — | US | disclosed |
| US-20190016724-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
| US-20190016724-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
| EP-2791140-B1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-06-15 | — | — | EP | disclosed |
| EP-2791140-B1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | Bayer Pharma AG (DE) | 2016-06-15 | — | — | EP | disclosed |
| US-9206184-B2 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206184-B2 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-9206184-B2 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20140336173-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336173-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336173-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-11-13 | — | — | US | disclosed |
| EP-2791140-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013087578-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013087578-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-06-20 | — | — | WO | disclosed |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153745-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | NR5A2, FGFR1, FGFR3 | FGFR1 2/4885FGFR3 3/4885ACVRL1 543/4885 |
| US-20130158000-A1 | Disubstituted benzothienyl-pyrrolotriazines and uses thereof | STK25, CDK5, JAK2 | FGFR1 216/4885FGFR3 580/4885ACVRL1 2441/4885 |
| US-20140336173-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | NR5A2, NR2C2, FGFR1 | FGFR1 3/4885FGFR3 4/4885ACVRL1 598/4885 |
| US-20190016724-A1 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | FGFR1, NR5A2, FGFR3 | FGFR1 1/4885FGFR3 3/4885ACVRL1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.